The U.S. Food and Drug Administration today approved a new indication for Jardiance (empagliflozin) to reduce the risk of cardiovascular d...

The sodium-glucose cotransporter 2 inhibitor empagliflozin slows renal progression and averts clinical events, shows further analysis of t...

In continuation of my update on  Empagliflozin Empagliflozin (trade name: Jardiance) has been approved since May 2014 for adults...

In continuation of my update on  Empagliflozin For the first time, research shows that a type 2 diabetes drug significantly reduc...

We know that, Empagliflozin (see structure) is a SGLT2 inhibitor which is being investigated in clinical trials for the oral treatment ...